Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Role of protein biomarkers in the detection of high-grade disease in cervical cancer screening programs.

Brown CA, Bogers J, Sahebali S, Depuydt CE, De Prins F, Malinowski DP.

J Oncol. 2012;2012:289315. doi: 10.1155/2012/289315. Epub 2012 Feb 28.

2.

Improved abnormal Pap smear triage using cervical cancer biomarkers.

Killeen JL, Dye T, Grace C, Hiraoka M.

J Low Genit Tract Dis. 2014 Jan;18(1):1-7. doi: 10.1097/LGT.0b013e31828aeb39.

PMID:
23760145
3.

Anal dysplasia screening: an evidence-based analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2007;7(4):1-43. Epub 2007 Jun 1.

4.

Immunostaining of p16(INK4a)/Ki-67 and L1 capsid protein on liquid-based cytology specimens obtained from ASC-H and LSIL-H cases.

Byun SW, Lee A, Kim S, Choi YJ, Lee YS, Park JS.

Int J Med Sci. 2013 Sep 12;10(12):1602-7. doi: 10.7150/ijms.6526. eCollection 2013.

5.

Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries.

Cuzick J, Arbyn M, Sankaranarayanan R, Tsu V, Ronco G, Mayrand MH, Dillner J, Meijer CJ.

Vaccine. 2008 Aug 19;26 Suppl 10:K29-41. doi: 10.1016/j.vaccine.2008.06.019. Review.

PMID:
18847555
6.

Role of p16(INK4a) cytology testing as an adjunct to enhance the diagnostic specificity and accuracy in human papillomavirus-positive women within an organized cervical cancer screening program.

Gustinucci D, Passamonti B, Cesarini E, Butera D, Palmieri EA, Bulletti S, Carlani A, Staiano M, D'Amico MR, D'Angelo V, Di Dato E, Martinelli N, Malaspina M, Spita N, Tintori B, Fulciniti F.

Acta Cytol. 2012;56(5):506-14. doi: 10.1159/000338979. Epub 2012 Sep 27.

PMID:
23075891
7.

Screening for cervical cancer: new alternatives and research.

Lörincz AT.

Salud Publica Mex. 2003;45 Suppl 3:S376-87. Review.

PMID:
14746031
8.

Interpretation of p16(INK4a) /Ki-67 dual immunostaining for the triage of human papillomavirus-positive women by experts and nonexperts in cervical cytology.

Allia E, Ronco G, Coccia A, Luparia P, Macrì L, Fiorito C, Maletta F, Deambrogio C, Tunesi S, De Marco L, Gillio-Tos A, Sapino A, Ghiringhello B.

Cancer Cytopathol. 2015 Apr;123(4):212-8. doi: 10.1002/cncy.21511. Epub 2014 Dec 22.

9.
10.

[Health technology assessment report: Computer-assisted Pap test for cervical cancer screening].

Della Palma P, Moresco L, Giorgi Rossi P.

Epidemiol Prev. 2012 Sep-Oct;36(5 Suppl 3):e1-43. Italian.

11.

[Precancerous lesions of the cervix. Biomarkers in cytological diagnosis].

Schmidt D.

Pathologe. 2011 Nov;32(6):484-90. doi: 10.1007/s00292-011-1478-3. Review. German.

PMID:
21922253
12.

[Cervical cancer screening: past--present--future].

Breitenecker G.

Pathologe. 2009 Dec;30 Suppl 2:128-35. doi: 10.1007/s00292-009-1189-1. German.

PMID:
19756616
13.

Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.

Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J.

Vaccine. 2012 Nov 20;30 Suppl 5:F88-99. doi: 10.1016/j.vaccine.2012.06.095. Review. Erratum in: Vaccine. 2013 Dec 16;31(52):6266.

PMID:
23199969
15.

The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.

C Kitchener H, Canfell K, Gilham C, Sargent A, Roberts C, Desai M, Peto J.

Health Technol Assess. 2014 Apr;18(23):1-196. doi: 10.3310/hta18230.

16.

[Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].

Ronco G, Biggeri A, Confortini M, Naldoni C, Segnan N, Sideri M, Zappa M, Zorzi M, Calvia M, Accetta G, Giordano L, Cogo C, Carozzi F, Gillio Tos A, Arbyn M, Mejier CJ, Snijders PJ, Cuzick J, Giorgi Rossi P.

Epidemiol Prev. 2012 May-Aug;36(3-4 Suppl 1):e1-72. Italian.

17.

Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.

Leinonen M, Nieminen P, Kotaniemi-Talonen L, Malila N, Tarkkanen J, Laurila P, Anttila A.

J Natl Cancer Inst. 2009 Dec 2;101(23):1612-23. doi: 10.1093/jnci/djp367. Epub 2009 Nov 9.

PMID:
19903804
18.

Cervical FISH Testing for Triage and Support of Challenging Diagnoses: A Case Study of 2 Patients.

Hopley R, Gillespie A.

Lab Med. 2016 Feb;47(1):52-6. doi: 10.1093/labmed/lmv003.

PMID:
26732782
19.

Human papillomavirus: science and technologies for the elimination of cervical cancer.

Bosch FX.

Expert Opin Pharmacother. 2011 Oct;12(14):2189-204. doi: 10.1517/14656566.2011.596527. Epub 2011 Jul 15. Review.

PMID:
21756205
20.

Can Genomic Amplification of Human Telomerase Gene and C-MYC in Liquid-Based Cytological Specimens Be Used as a Method for Opportunistic Cervical Cancer Screening?

Gao K, Eurasian M, Zhang J, Wei Y, Zheng Q, Ye H, Li L.

Gynecol Obstet Invest. 2015;80(3):153-63. doi: 10.1159/000371760. Epub 2015 Apr 1.

PMID:
25832290

Supplemental Content

Support Center